HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals

Clinical Infectious Diseases

Volumn 55, Issue 4, 2012, Pages 600-607

  Lang, Sylvie ^a   Mary Krause, Murielle ^a   Simon, Anne ^b   Partisani, Marialuisa ^f   Gilquin, Jacques ^d   Cotte, Laurent ^g   Boccara, Franck ^a,e   Costagliola, Dominique ^a,c  

^a INSERM   (France)

^b Service de Médecine Interne I   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR; VIRUS RNA; ZALCITABINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; VIROLOGY; VIRUS REPLICATION;

ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 84864469250     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis489     Document Type: Article

References (55)

1. Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD. Trends in perimortal conditions and mortality rates among HIVinfected patients. AIDS 2007; 21:2093-100.
2. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). JAIDS 2008; 48:590-8.
3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
4. Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus compared with the general population. Clin Infect Dis 2003; 37:292-8.
5. Friis-Møller N, Reiss P, Sabin CA; for the D:A:D study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35.
6. Worm WS, Sabin C, Weber R, et al.; for the D:A:D Study Group. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-30.
7. 4. Arch Intern Med 2010; 170:1228-38.
8. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS. Circulation 2008; 118:198-210.
9. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albumineria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651-8.
10. 4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
11. Marin B, Thiébaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-53.
12. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243-53.
13. 4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615-24.
14. Hsue P, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus- specific T-cell responses. AIDS 2006; 20:2275-83.
15. Kaplan RC, Sinclair E, Landay AL, et al. T-cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452-63.
16. Grunfeld C, Delaney JAC, Wanke C, et al.; for the study of Fat Redistribution and Metabolic Change in HIV infection. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from FRAM study. AIDS 2009; 23:1841-9.
17. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. JAIDS 2010; 55:615-9.
18. Law MG, Friis-Møller N, Weber R, et al. Modeling the 3-year risk of myocardial infarction among participants in the data collection on averse events of anti-HIV drugs (DAD) study. HIV Med 2003; 4:1-10.
19. Law MG, Friis-Møller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med 2006; 7:218-30.
20. Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17:491-501.
21. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from SMART trial. Antiviral Therapy 2008; 13:177-87.
22. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-Term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929-40.
23. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database (RAMQ). JAIDS 2011; 57:245-53.
24. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289-98.
25. Bedimo RJ, Wesfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84-91.
26. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P; for the WHO MONICA Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 MONICA Project populations. Lancet 1999; 353:1547-57.
27. Liddell FDK, McDonald JC, Thomas DC. Methods of cohort analysis: appraisal by application to asbestos mining. J R Stat Soc (A) 1977; 140:469-91.
28. Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc 1983; 78:1-12.
29. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-6.
30. Hulley SB, Cummings SR, Browner WS. Designing a cohort study. In: Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. Designing Clinical Research. Philadelphia, USA: Wolters Kluwer/Lippincott Williams & Wilkins; 2007; 97-107.
31. Yeni P, Barbier MF, Blanche S, et al. Rapport 2008: Prise en charge médicale des patients infectés par le VIH. Paris, France: Medecine- Sciences/Flammarion, 2008.
32. Luepker RV, Apple FS, Christenson RH, et al.; AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. Circulation 2003; 108:2543-9.
33. Mc Cord J, Jneid H, Hollander JE, et al.; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Management of cocaine-associated chest pain and myocardial infection. Circulation 2008; 117:1897-907.
34. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29:932-40.
35. Ancelle-Park RA. Expanded European AIDS definition. Lancet 1993; 341:441.
36. Janssen KJM, Donders ART, Frank E, et al. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol 2010; 63:721-7.
37. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18:681-94.
38. Rubin D. Multiple imputation for non response in surveys. New York: Wiley, 1987.
39. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129:125-37.
40. Lanoy E, Lewden C, Lièvre L, et al. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates. HIV Medecine 2009; 10:236-45.
41. Yarnell JWG. The PRIME study: classical risk factors do not explain the several fold in risk of coronary heart disease between France and Northern Ireland. Q J Med 1998; 91:667-76.
42. Cooney MT, Dudina A, d'Agostino RB, Graham IM. Cardiovascular risk-estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future? Circulation 2010; 122:300-10.
43. Acharjee S, Qin J, Murphy SA, McCabe C, Cannon CP. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial). Am J Cardiol 2010; 105:619-23.
44. Conney MT, Dudina A, De Bacquer D, et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil 2009; 16:304-14.
45. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977; 62:707-14.
46. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease: 10-year follow-up of the Hoorn study. Eur Heart J 2003; 24:1406-13.
47. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004; 90:1398-403.
48. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24:1228-30.
49. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083-96.
50. Hotchkiss JW, Leyland AH. The relationship between body size and mortality in the linked Scottish health surveys: cross-sectional surveys follow-up. Int J Obes 2011; 35:838-51.
51. Boccara F, Mary-Krause M, Teiger E, et al.; on behalf the PACS investigators. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur Heart J 2011; 32:41-50.
52. Caron-Debarle M, Boccara F, Lagathu C, et al. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr Pharm Des 2010; 16:3352-60.
53. Yusuf S, Hawken S, Ôunpuu S, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640-49.
54. 4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43.
55. Guihot A, Dentone C, Parizot C, et al. Nadir drives persistence of monocytes and T lymphocytes activation in virologically suppressed HIV-infected patients. Scientific poster presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Abstract D-198.